Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Purchases $1,827,149.97 in Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus acquired 180,727 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, November 17th. The shares were purchased at an average cost of $10.11 per share, for a total transaction of $1,827,149.97. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Public Equities L.P. Invus also recently made the following trade(s):

  • On Friday, November 10th, Public Equities L.P. Invus acquired 145,680 shares of Lexicon Pharmaceuticals stock. The shares were purchased at an average cost of $9.74 per share, for a total transaction of $1,418,923.20.
  • On Tuesday, November 14th, Public Equities L.P. Invus acquired 575,946 shares of Lexicon Pharmaceuticals stock. The shares were purchased at an average cost of $9.64 per share, for a total transaction of $5,552,119.44.

Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded up $0.23 during mid-day trading on Friday, hitting $10.45. The stock had a trading volume of 600,969 shares, compared to its average volume of 942,832. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.65 and a current ratio of 1.66. Lexicon Pharmaceuticals, Inc. has a one year low of $8.07 and a one year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The company had revenue of $26.94 million for the quarter, compared to the consensus estimate of $27.97 million. During the same quarter in the prior year, the business posted ($0.35) EPS. The firm’s quarterly revenue was down 2.8% on a year-over-year basis. analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC increased its position in shares of Lexicon Pharmaceuticals by 0.9% in the 2nd quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock valued at $259,668,000 after buying an additional 137,421 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Lexicon Pharmaceuticals by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after buying an additional 585,222 shares in the last quarter. USS Investment Management Ltd bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at $57,705,000. Eagle Asset Management Inc. increased its position in shares of Lexicon Pharmaceuticals by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,861,065 shares of the biopharmaceutical company’s stock valued at $47,064,000 after buying an additional 8,756 shares in the last quarter. Finally, State Street Corp increased its position in shares of Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock valued at $32,363,000 after buying an additional 326,088 shares in the last quarter.

Several research analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $38.00 price objective on shares of Lexicon Pharmaceuticals in a report on Thursday. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th. Finally, BidaskClub downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $28.50.

TRADEMARK VIOLATION NOTICE: “Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Purchases $1,827,149.97 in Stock” was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://weekherald.com/2017/12/04/lexicon-pharmaceuticals-inc-lxrx-director-public-equities-l-p-invus-acquires-180727-shares-of-stock.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply